AB1827-HPR PAIN MANAGEMENT IN OLDER POPULATION FROM GERMANY AND SWEDEN: SUB-GROUP ANALYSIS FROM A TOPICAL DICLOFENAC PROSPECTIVE REAL-WORLD EVIDENCE STUDY
Authors: V. Rampartaap, K. Fabrikant, D. Nair, V. Sood, G. Shanga, T. Wilcox, J. R. Norrefalk, E. Csoke
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Adequate pain management in older individuals is essential to support functional lifestyle and enable robust quality of life (QoL). Topical non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac gel, with limited systemic exposure, provide a better pharmacological alternative to oral NSAIDs for musculoskeletal pain management especially in elderly due to favorable benefit-risk profile<sup>[1]</sup>. <h3>Objectives</h3> To evaluate impact of over the counter (OTC) topical diclofenac (1.16% &amp; 2.32%) use in an older German and Swedish population on different aspects related to QoL such as pain, functional status, and treatment satisfaction. <h3>Methods</h3> A subgroup analyses of older participants (≥65 years) from a prospective real-world evidence study conducted among 731 adult (≥18 years) consumers (467 in Germany and 264 in Sweden) of OTC topical diclofenac (1.16% &amp; 2.32%). Treatment satisfaction, functional status and pain relief were assessed using electronic surveys (baseline, Week 4, and Week 12) via personalized link. Numerical Rating Scale (NRS-11) and Likert scale were used for questionnaire-based response collection. <h3>Results</h3> Data from 279 (72.3%) older participants, 203 German and 76 Swedish, were included. Baseline characteristics of participants and reported outcomes are shown in Table 1. Majority purchased 2.32% strength, were repeat users and reported having previously identified cardiovascular conditions. Improvement in pain score ≥ 1 point was observed in &gt;57% of users at Week 12. Participants reported reduction of pain interference in different functional activities at Week 4 and 12. &gt;70% of participants were satisfied with the treatment at Week 4 and &gt;75% at Week 12. <h3>Conclusion</h3> Older participants reported reduction in pain over time, improvements in their ability to participate in daily life activities, treatment satisfaction with the use of OTC topical diclofenac and thus improved QoL. <h3>Reference</h3> [1] da Costa BR, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021 12;375:n2321. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Vishal Rampartaap Shareholder of: Yes, Speakers bureau: Yes, as an employee of Haleon, Employee of: Haleon, Kate Fabrikant Shareholder of: Yes, Speakers bureau: Yes, as an employee of Haleon, Employee of: Haleon, Deepika Nair Shareholder of: Yes, Speakers bureau: Yes, as an employee of Haleon, Employee of: Haleon, Vidhu Sood Shareholder of: Yes, Speakers bureau: Yes, as an employee of Haleon, Employee of: Haleon, Gilbert Shanga Shareholder of: Yes, Speakers bureau: Yes, as an employee of Haleon, Employee of: Haleon, Terry Wilcox Employee of: Yes, Jan-Rickard Norrefalk: None declared, Emese Csoke Employee of: Yes.